Alcoholism Clinical Trial
Official title:
A Novel Compound for Alcoholism Treatment: A Translational Strategy
Background:
- Hormones are naturally occurring chemicals in your body. Ghrelin is a hormone that is
mainly produced by the stomach and stimulates appetite. Some studies suggest it may stimulate
alcohol craving and use. Drugs have been developed that block ghrelin. Researchers want to
know if people can tolerate a particular drug that blocks ghrelin. It will be given at two
dose levels, combined with alcohol.
Objective:
- To determine if a drug that may decrease alcohol consumption when given along with alcohol
is safe and tolerable.
Eligibility:
- Healthy adults 21-65 years old who have 14 (women) to 21 (men) drinks a week.
- No one of childbearing potential can participate.
Design:
- Participants will have 3 inpatient clinic visits; each will last 4 days.
- They will have physical exam and blood and urine tests.
- They will have breath tests for alcohol and smoking.
- They will answer health and mood questions.
- Researchers will measure their reaction to smelling alcohol and tasting a sweet drink.
- They will eat only the food provided by the clinic. They will keep a food diary 1 day
before each stay.
- They will be randomly assigned to take the study drug or placebo 5 times each stay.
- On Day 3, they will drink alcohol after taking the drug. They will give many blood
samples that day through a tube inserted in their skin.
- Smokers can take smoke breaks. Once, they will smoke a cigarette through a device.
- One week after the last stay, participants will have a follow-up visit to answer
questions.
Objective: Ghrelin is a 28-aminoacid peptide that stimulates appetite and food intake. It is
an endogenous ligand for the growth hormone secretagogue receptor (GHSR1a). Preclinical
studies suggest that ghrelin modulates alcohol reward processing. Furthermore, findings from
a translational human lab study at Brown University (PI: Leggio) indicate that intravenous
(IV) ghrelin administration, compared to placebo, results in an acute increase in craving for
alcohol during a cue-reactivity experiment in alcoholic individuals. Therefore, an orally
bioavailable, ghrelin receptor antagonist, that can pass through the blood brain barrier
holds particular promise as an AD treatment. This project has been recently funded by NCATS.
The goals of this protocol are to generate preliminary evidence on the safety and efficacy of
a ghrelin receptor antagonist (GHSR1a antagonist), PF-05190457, an existing molecule
available under the NIH-Industry Pilot Program at NCATS.
Study population: Non-treatment seeking heavy drinkers (n =20). The study will be conducted
in the Inpatient Unit at the NIAAA Intramural Clinical Program.
Study Design: Single-blind dose-escalating placebo-controlled inpatient study using
PF-05190457, in non-treatment seeking heavy drinking subjects. This Phase 1b study will be a
within-subject design.
Outcome measures: Primary objectives will be to determine: 1) the number of adverse events
(AEs) experienced, compared between all three PF-05190457 dose categories (0mg or placebo,
50mg, and 100mg b.i.d.); and 2) the total concentration of the drug, compared between the two
non-placebo drug doses (50mg and 100mg b.i.d.), when co-administered with alcohol. We
hypothesize that both doses of PF-05190457, as compared to placebo, will not result in an
increased number of AEs. As a secondary objective, we will determine whether PF-05190457
dose-dependently affects the subjective effects of alcohol and craving. We will include
pharmacokinetics (PK) and pharmacodynamic (PD) investigations conducted at University of
Rhode Island (URI; Associate Investigator: Akhlaghi). The PK/PD component will include (i)
measuring total, unbound or tissue concentrations of the drug using liquid chromatography
tandem mass spectrometry (LC-MS/MS) and evaluation of biomarkers of effect and (ii)
estimation of PK and PD parameters by the use of conventional and semi-mechanistic modeling
approaches to assist in identifying an optimal dosing regimen of the drug in AD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 |